Genetic Technologies Limited (GENE) Research

Genetic Technologies Limited (GENE) is a molecular diagnostics company specializing in providing predictive testing and assessment tools. These solutions empower healthcare professionals to better manage women's health concerns in both Australia and the United States. Its flagship product, BREVAGenplus, is a clinically validated risk assessment test specifically designed for non-hereditary breast cancer. This innovative test is promoted to various medical specialists, including professionals in breast healthcare and imaging centers, obstetricians/gynecologists, and breast cancer risk assessment experts like breast surgeons. Beyond BREVAGenplus, the company's portfolio includes other cancer risk assessment tests marketed under the 'GeneType' brand, notably 'GeneType for Colorectal Cancer' and 'GeneType for Breast Cancer'. Furthermore, Genetic Technologies is actively developing additional risk assessment tools for a diverse range of conditions, such as cardiovascular diseases, type 2 diabetes, prostate cancer, and melanoma. Its services extend to general genetic testing, encompassing applications in medical, animal, forensic, and plant diagnostics. Genetic Technologies maintains active research and collaboration agreements with several prestigious institutions, including the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, The Ohio State University, and Shivom. The company was established in 1987 and operates from its headquarters in Fitzroy, Australia.

Open Genetic Technologies Limited (GENE) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.